Cargando…
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors
Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2). We developed a high sensitivity (HS) assay utilizing wild-type blocking polymerase chain reaction achiev...
Autores principales: | Albitar, Adam, Ma, Wanlong, DeDios, Ivan, Estella, Jeffrey, Ahn, Inhye, Farooqui, Mohammed, Wiestner, Adrian, Albitar, Maher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392298/ https://www.ncbi.nlm.nih.gov/pubmed/28212557 http://dx.doi.org/10.18632/oncotarget.15316 |
Ejemplares similares
-
BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022) -
Role of the Btk-PLCγ2 Signaling Pathway in the Bone Destruction of Apical Periodontitis
por: Wang, Lina, et al.
Publicado: (2019) -
The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2
por: Spaargaren, Marcel, et al.
Publicado: (2003) -
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021) -
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)